91 results on '"P. G. Richardson"'
Search Results
2. P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY
3. P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
4. Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
5. PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY
6. PF595 POMALIDOMIDE + BORTEZOMIB + LOW-DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE-PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL
7. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
8. S1605 HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)
9. Debate - Change Therapy for High/Low Risk Patients - No
10. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
11. Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
12. Targeting the Ubiquitin-proteasome System in Multiple Myeloma: Examining the Roots of Success
13. Safety Profile of Oral Ixazomib: Experience from 761 Patients (Pts) Across 14 Phase 1 or Phase 1/2 Clinical Studies
14. Analysis of Second Primary Malignancies (SPMs) in CALGB (Alliance)/ECOG/BMT CTN 100104
15. HDAC Inhibition in Multiple Myeloma with a Focus on Selective HDAC6 Inhibition
16. Phase 1/2 dose-escalation study of marizomib (MRZ, NPI-0052) plus low dose dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma; study NPI-0052-101 (NCT00461045)
17. Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: results from a multicenter phase 2 trial
18. Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT)
19. PSY42 Patient-Reported Outcome (PRO) Instrument for Detection of Peripheral Neuropathy (PN) in Patients With Multiple Myeloma (MM): The FACT/GOG-Ntx
20. Relative merits of pre/post-Doppler STAP
21. Cross modulation cancellation for airborne phased array radar
22. Array signal processing using digital subarrays
23. Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study
24. Subgroup Analysis by Prior Treatment of the Efficacy and Safety of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma in the PANORAMA 1 Study
25. Transplant Eligible Maintenance
26. The current unmet medical needs in the treatment and management of multiple myeloma (MM)
27. Four phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma in the newly-diagnosed, relapsed/refractory, and maintenance settings: TOURMALINE-MM1, -MM2, -MM3, and -MM4
28. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
29. 010 Quality, performance and performance indicators: use of a standardised template to develop and promote quality and performance in Australasian Emergency Departments
30. Basilar artery thrombosis
31. A347 Phase I Trial of Perifosine, Lenalidomide, and Dexamethasone in Relapsed or Refractory Myeloma
32. B257 Vorinostat in Combination with Other Anti-MM Agents
33. B037 CAL-101: A Selective Inhibitor of PI3K p110D for the Treatment of Multiple Myeloma
34. A220 Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone
35. A247 Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide (VDCR) Has High Efficacy in First-Line MM
36. A533 RAD001: Phase II Trial in Relapsed/Refractory Waldenström Macroglobulinemia, the DFCI Experience
37. A217 Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial
38. A535 Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenström Macroglobulinemia
39. A241 Vorinostat/Lenalidomide/Dexamethasone: A Phase I Study
40. Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
41. PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma
42. Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study
43. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study
44. PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM)
45. Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma
46. Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma
47. Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study
48. Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study
49. Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM)
50. Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenström's macroglobulinemia, and effect on miRNA expression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.